New York, July 16, 2024 - PRISM MarketView - Shares in psychedelic-derived therapeutics company, Clearmind Medicine (Nasdaq: CMND), surged on Monday after the company announced it will participate in the 2024 Psychedelic Medicine – Israel conference. The annual event brings together leading experts and researchers from around the world in the field of psychedelic medicine. Clearmind’s share price settled up 30.58%, reaching $2.22 and leading the PRISM Emerging Psychedelics Index.
Clearmind’s presentations at the conference will focus on “5-Methoxy-2-Aminoindane (MEAI) as a Binge Behavior Regulator” and “5-methoxy-2-aminoindane (MEAI), a mild psychedelic agent, attenuates diet-induced obesity” highlighting promising results implicating MEAI in regulating binge behaviors and attenuating obesity.
“We are honored to present our groundbreaking research at the Psychedelic Medicine – Israel 2024 conference. MEAI has shown remarkable potential in regulating several binge behaviors and treating overweight, and we are excited to share these findings with the scientific community. Our commitment to pioneering research in psychedelic-derived therapeutics continues to drive us forward as we seek to address major health challenges.”
Dr. Zullof-Shani, CEO of Clearmind Medicine
Psychedelic Medicine – Israel will provide an interdisciplinary international forum for exchanging ideas, unveiling innovations and training in the basics of psychedelic assisted psychotherapy.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. The Company’s intellectual portfolio currently consists of eighteen patent families including 28 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. For further information visit: https://www.clearmindmedicine.com
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on Twitter.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities